Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 4Terminated 2Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 12Lymphoid 2Tumor-Agnostic 1Thoracic 1Sarcoma 1Plasma cell 1Other solid neoplasm 1Myeloid 1Gynecologic 1Gastrointestinal 1Dermatologic 1CNS 1

Conditions

Carcinoma, Hepatocellular 1

Interventions

Oxaliplatin 288Capecitabine 218Fluorouracil 212Irinotecan 145Leucovorin 139Gemcitabine 124S 1 (combination) 110apatinib 109Cisplatin 102Drug Therapy 98Bevacizumab 98Radiotherapy 97Paclitaxel 97camrelizumab 89sintilimab 79Cetuximab 75lenvatinib 62Neoadjuvant Therapy 61tislelizumab 55Surgical Procedures, Operative 54Sorafenib 53Folfox protocol 53toripalimab 52Docetaxel 52130-nm albumin-bound paclitaxel 47Laparoscopy 41HMPL-013 40XELOX 39Radiosurgery 36Albumin-Bound Paclitaxel 36

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Arsenic Trioxide × Gastrointestinal × Clear all
NCT02956772 2017-02-23

Transcatheter Arterial Chemoembolization (TACE) in Combination With Arsenic Trioxide Versus TACE in the Treatment of Middle-advanced Primary Hepatocellular Carcinoma (HCC) Patients

Hunan Provincial People's Hospital

Phase 2 Unknown
190 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡